Study of LM-305 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) and Other Plasma Cell Diseases
Launched by LANOVA MEDICINES LIMITED · Dec 1, 2022
Trial Information
Current as of January 16, 2025
Withdrawn
Keywords
ClinConnect Summary
A Phase I/II, Open-Label, Multiple Centre Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of LM-305 in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- Subjects will be enrolled into the study only if they meet all of the following inclusion criteria:
- • 1. Subjects who are fully informed of the purpose, nature, method and possible adverse reactions of the study, and are willing to participate in the study and sign the informed consent form (ICF) prior to any procedure.
- • 2. Aged ≥18 years old when sign the ICF, male or female.
- • 3. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1。
- • 4. Life expectancy ≥ 6 months.
- • 5. Subjects must show appropriate organ and marrow function in laboratory examinations
- Exclusion Criteria:
- Subjects will be excluded from the study, if they meet any of the following criteria:
- • 1. A history of other malignant tumors than multiple myeloma within 3 years prior to first dosing
- • 2. Subjects who have severe cardiovascular disease。
- • 3. Use of any live attenuated vaccines within 28 da ys prior to 1st dosing of IMP.
- • 4. Child-bearing potential female who have positive results in pregnancy test or are lactating.
- • 5. Subject who is judged as not eligible to participate in this study by the investigator.
Trial Officials
Depei Wu
Principal Investigator
The First Affiliated Hospital of Soochow University
About Lanova Medicines Limited
Lanova Medicines Limited is a clinical research organization dedicated to advancing innovative therapeutic solutions across various disease areas. With a strong emphasis on precision medicine, the company focuses on developing and optimizing treatments that enhance patient outcomes. Leveraging a team of experienced researchers and state-of-the-art technology, Lanova Medicines Limited is committed to conducting rigorous clinical trials that adhere to the highest standards of scientific integrity and regulatory compliance. Their mission is to bring transformative therapies to market, ultimately improving the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Similar Trials